Gastrointestinal stromal tumors (GIST) 

Gastrointestinal stromal tumors (GIST) are relatively rare (1-3% of all gastrointestinal malignancies); however, their incidence is steadily rising. In the past, radical abdominal surgery was the only prospect for contending with this disease. However, scientists today have succeeded in defining that mutations in the Kit gene or PDGFRA gene were found to be the driving force of the behavior of most cases of this disease. Deciphering the disease's biological "code", enables physicians to treat the disease using novel biological drugs which target the mechanism of the tumor and suppresses tumor growth. Today, Oncotest – Advantest offers tests which can ascertain whether the use of this advanced drug would be beneficial to each patient.